IVA
Inventiva's Strong First Half Performance Sets Stage for Exciting Second Half
Inventiva, a biopharmaceutical company dedicated to developing novel therapies for major unmet medical needs, has reported strong financial results in its first half of 2026. The company's recent conference call provided valuable insights into its progress and priorities, setting the stage for an exciting second half. Andrew Obenshain,